Global pain management devices market is growing at a considerable CAGR of 7.3% during the forecast period (2024-2031). The market growth is driven by the increasing prevalence of chronic diseases with the easy availability of technically advanced pain management devices. Additionally, supportive reimbursement policies and the adverse effects of pain medications are contributing to the market growth. However, the high cost of pain management devices, lack of awareness regarding the availability, and insufficiency of a pain specialist in underdeveloped and some emerging economies are restraining the market growth.
The global pain management devices market is segmented by application (cancer pain, neuropathic pain, musculoskeletal pain, facial and migraine pain, other (trauma)), by device type (neurostimulators devices, analgesic infusion pumps, ablation devices), and by geographies (North America, Europe, Asia-Pacific, and Rest of the World).
Browse the full report description of “Global Pain Management Devices Market by Application (Cancer Pain, Neuropathic Pain, Musculoskeletal Pain, Facial and Migraine Pain, Other (Trauma)), by Device Type (Neurostimulators Devices, Analgesic Infusion Pumps, Ablation Devices) - Industry Size, Global Trends, Competitive Analysis and Forecast, 2024-2031” at https://www.omrglobal.com/industry-reports/pain-management-devices-market
The major players in the global pain management devices market include Abbott Laboratories, B. Braun Melsungen AG, Johnson & Johnson Services, Inc., Medtronic, NEVRO Corp., and Pfizer Inc. among others. The market players are contributing significantly to the market growth, by the adoption of various business strategies, such as collaborations, mergers and acquisitions, product portfolio diversification, and more.
Recent Developments
- In September 2024, Zynex Inc. announced FDA clearance of its new TensWave device. The product features a portable design and provides pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, clinically proven to reduce chronic and acute pain without the need for medication.
- In August 2024, researchers at the University of Utah’s John and Marcia Price College of Engineering and Spencer Fox Eccles School of Medicine published promising findings about an experimental therapy to provide relief after a single treatment session. Diadem, a new biomedical device uses ultrasound to noninvasively stimulate deep brain regions, potentially disrupting the faulty signals that lead to chronic pain.
- In July 2024, Boston Scientific Corp. announced the positive five-year pooled results for the Intracept™ Intraosseous Nerve Ablation System that measures outcomes across three clinical trials in the treatment of vertebrogenic low back pain, at the sixth annual American Society of Pain & Neuroscience (ASPN) conference, in Florida.
- In April 2024, Vertex Pharmaceuticals Inc. announced advancements in the suzetrigine pain program, the potential new class of medicine for acute and neuropathic pain. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
- In April 2024, Medtronic plc announced the US Food and Drug Administration (FDA) approval of the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. It is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real-time, keeping therapy in harmony with the motions of daily life.
- In November 2023, BehaVR, and Fern Health, announced the signing of an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering will be branded as RealizedCare, with a care management platform powered by DTx technology.
- In March 2023, the Defense Appropriations Act provided funding for the Chronic Pain Management Research Program (CPMRP) to support and promote innovative, high-impact research to prevent the development and improve the management of chronic pain. The Department of Defense emphasized the utilization and implementation of non-opioid therapies or non-addictive treatment methods.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/pain-management-devices-market